BioCentury
ARTICLE | Clinical News

Recilisib sodium: Phase I data

October 22, 2012 7:00 AM UTC

A placebo-controlled Phase I trial in 20 healthy volunteers showed that a 2-dose regimen of 200 and 400 mg subcutaneous Ex-RAD given at different injection sites was well tolerated with no clinically ...